Novel concepts on the horizon for the diagnosis and treatment of mesothelioma

  • Alessandra Curioni Fontecedro
Thoracic Malignancies ESMO Congress 2021

Malignant pleural mesothelioma is a rare and fatal disease with very little improvement in survival in recent years, mirroring very limited therapeutic advances. After a long-awaited time, improvement in patient survival was achieved with the introduction of nivolumab plus ipilimumab in the first-line setting, as demonstrated in the CheckMate 743 trial.

Alessandra Curioni-Fontecedro

At the annual ESMO Congress this year, 3-year overall survival (OS) data were presented with longer survival for patients receiving immunotherapy compared with standard chemotherapy. Moreover, for mesothelioma, a longer right tail of the survival curve in the immunotherapy arm was shown, in line with previous studies in patients with melanoma and non-small-cell lung cancer (Lancet Oncol. 2019 Sep;20(9):1239-1251; N Engl J Med. 2019 Oct 17;381(16):1535-1546J Clin Oncol. 2021;39(suppl 15):9016). This demonstrates immune system memory to fight mesothelioma in the long term. In addition to the presentation of results of treatment with conventional therapies, we have also seen reports of novel treatments this year, such as in Abstract 959O, where the authors demonstrated that the use of T cells transduced with a modified T-cell-receptor targeting mesothelin could be efficient in patients with mesothelioma. Despite these results being preliminary, these data underline the importance of new strategies for this disease.

In addition, molecular features of mesothelioma have been revealed using next-generation sequencing of the largest cohort ever analysed, consisting of more than 1,000 mesothelioma samples. The analysis identified a proportion of patients with targetable alterations, opening new treatment options for patients with mesothelioma (Abstract 1734P).

Despite being rare, mesothelioma represents a major challenge for clinicians, but findings presented at this ESMO Congress have the potential to open new options for diagnosis and treatment with the aim of improving patient outcome.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.